Table 2.
Different novel formulation evaluation studies before incorporating into hydrogel.
| API-Novel Formulation | Droplet/Particle Range | Drug Content/Entrapment Efficiency (%) | PDI | Zeta Potential (mV) | pH | Viscosity | Shape | Time | DR (%) | References |
|---|---|---|---|---|---|---|---|---|---|---|
| RVT-LS | 100 to 200 nm (Average 158 ± 22 nm) |
85 ± 2 | 0.077 | −6.72 ± 2.47 | NP | appropriate viscosity (NM) | Spherical | 8 h | 61 | [32] |
| Vit C-SDEDDS | 0.06 to 60.26 μm (Average 17.13 ± 2.50 μm) |
NP | NP | NP | NP | NP | NP | NP | NP | [33] |
| ROS-NE | 180.57 ± 1.82 to 224.67 ± 2.31 nm | 98.59 ± 2.12 to 107.69 ± 6.28 | 0.123 ± 0.021 to 0.230 ± 0.036 | −39.65 ± 1.53 to 46.17 ± 3.90 | 3.85 ± 0.07 to 4.73 ± 0.07 | 1.1 to 1.3 cps | NP | 8 h | 71.8 ± 1.98 | [34] |
| PG-NE | 164.3 ± 7.4 nm | 96.2 ± 3.4 | 0.12 ± 0.03 | −48.9 ± 2.1 | 5.5 ± 0.2 | Near to 1 cps | NM | NP | NP | [35] |
| PENY-NC | 161 ± 4 nm | 95.2 ± 1.4 | 0.14 ± 0.01 | −15.7 ± 0.3 | 5.6 ± 0.1 | NP | Spherical | 3 h 24 h |
27 ± 1 67 ± 1 |
[36] |
| PENY-NE | 125 ± 6 nm | 88.7 ± 1.1 | 0.12 ± 0.01 | −10.8 ± 0.4 | 5.0 ± 0.7 | NP | Spherical | 3 h 24 h |
36 ± 2 77 ± 2 |
[36] |
| IBU-ME | 14.34 ± 0.98 nm | NP | 0.220 ± 0.075 | NP | 5.23 | 0.2025 ± 0.003 Pas | NP | 12 h | 46.78 ± 4.59 | [37] |
| TER-ME | 44.98 ± 27.34 nm | NP | NP | NP | NP | 77.98 ± 0.75 cp | Spherical | NP | NP | [38] |
| CUR-ME | 231.8 ± 7.6 nm | 99.50 | NP | NP | NP | NP | NP | NP | NP | [39] |
| BCN-NCY | 189.21 ± 0.36 nm | NP | NP | NP | NP | NP | Spherical Gel TEM showed network structure | 4 h | 65.3 ± 3.2 | [40] |
| SSD-CUBO | 152.3 to 389.6 nm | 86.05 ± 3.86 to 94.56 ± 1.40 | 0.25 ± 0.004 to 0.65 ± 0.45 | NP | NP | NP | Cubic | NP | NP | [41] |
NP: Not performed by the researchers; NM: Not mentioned by the researchers.